8-K: Azitra Reports Q3 2026 Results, Advances Dermatology Programs

Azitra, Inc. announced its third-quarter 2026 financial results and provided business updates, detailing progress in its ATR-COSF cosmetic and ATR-04 dermatology programs, with key data expected by year-end.

Summary

• Azitra, Inc. reported financial results for the quarter ended September 30, 2026.
• The company highlighted progress in its ATR-COSF program with ex vivo studies showing a reduction in fine lines and improved skin elasticity.
• Advancements were also noted for the ATR-04 program, with the completion of Cohort 1 of the Phase 1/2 trial and a recommendation to proceed to Cohort 2.
• The ATR-04 trial eligibility was expanded to include patients with KRAS and MEK inhibitor-associated rash.
• Research and Development expenses were $1.3 million for Q3 2026, an increase from $1.2 million in Q3 2025.
• General and Administrative expenses were $1.6 million for Q3 2026, consistent with $1.6 million in Q3 2025.
• The company reported a net loss of $3.0 million for Q3 2026, compared to $2.8 million in Q3 2025.
• As of September 30, 2026, Azitra had $3.8 million in cash and cash equivalents.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, highlighting promising clinical trial progress and encouraging ex vivo study results for key programs, balanced by continued operational expenses and a net loss.

Positives

• Promising ex vivo study results for ATR-COSF demonstrated a reduction in fine lines by approximately 50% after 48 hours and improved skin elasticity.
• Completion of Cohort 1 for the ATR-04 Phase 1/2 trial and a recommendation to advance to Cohort 2.
• Expansion of ATR-04 trial eligibility to include patients with KRAS and MEK inhibitor-associated rash, broadening potential patient reach.
• Anticipation of initial results from the first-in-human cosmetic study of ATR-COSF by year-end 2026.
• Anticipation of topline data from Cohort 1 of the ATR-04 Phase 1/2 trial in the fourth quarter of 2026.
• Potential for institutional investors to invest an additional $5.25 million to $10.5 million through financial instruments upon announcement of ATR-COSF results.

Negatives

• Net loss of $3.0 million for the quarter ended September 30, 2026, an increase from $2.8 million in the comparable period of 2025.
• Cash and cash equivalents of $3.8 million as of September 30, 2026, may require additional funding for ongoing operations and development.
• R&D expenses increased to $1.3 million in Q3 2026 from $1.2 million in Q3 2025.

Risks

• Potential for delays in clinical trials and their results.
• Enrollment delays in the ATR-04 trial.
• Protocol amendments may not facilitate recruitment or accelerate enrollment as anticipated.
• Delays in the provision of safety data or topline results for ATR-04, and such data may not be favorably received.
• Expanded patient populations for ATR-04 may present different safety or efficacy profiles.
• Results from Cohort 1 of ATR-04 may not be predictive of results in Cohort 2 or later-stage trials.
• Results from ex vivo and other preclinical studies may not be predictive of results in humans for ATR-COSF.
• The first-in-human study of ATR-COSF may be delayed or may not produce favorable results.

Future Outlook

The company anticipates reporting initial results from its first in-human cosmetic study of ATR-COSF and topline data from Cohort 1 of its ATR-04 Phase 1/2 trial by the end of 2026. Institutional investors have the opportunity to invest an additional $5.25 million to $10.5 million upon the announcement of ATR-COSF results.

Management Comments

• During the third quarter and recent weeks, we made substantial progress with our two priority programs, generating encouraging results for ATR-COSF and advancing ATR-04 forward in the clinic while broadening its potential to benefit more patients.
• We were very pleased to report research involving ATR-COSF demonstrating a single application of the product was able to reduce the appearance of fine lines and wrinkles by approximately 50% after 48 hours in laboratory studies, while our optimized formulation improved skin elasticity across every measure tested in a separate study.
• The recommendation to advance ATR-04 to Cohort 2 brings us closer to our goal of providing a new treatment option for patients whose debilitating skin rash can disrupt essential therapy.
• Additionally, by expanding the trial to address rash associated with KRAS and MEK inhibitors, including in patients with neurofibromatosis type 1 with MEK inhibitor-associated rash, we are broadening ATR-04s potential reach and expanding the eligible patient pool to support enrollment.
• We believe ATR-04 has the potential to become the first live biotherapeutic developed for skin rashes associated with cancer and MEK inhibitor treatment for neurofibromatosis treatments.
• The remainder of 2026 has the potential to be a defining period for Azitra as we expect to report initial results from our first in-human cosmetic study of ATR-COSF and topline data from Cohort 1 of our ATR-04 Phase 1/2 trial.

Industry Context

StockSavvy.ai notes that Azitra's progress aligns with the growing trend in precision dermatology and the development of novel therapies for specific patient populations. The company's focus on both cosmetic applications (ATR-COSF) and therapeutic treatments for debilitating rashes (ATR-04) positions it within two significant and expanding segments of the biopharmaceutical market.

Stakeholder Impact

• Shareholders may see potential upside if the upcoming trial results are positive and the additional capital is raised.
• Patients with targeted therapy-associated rashes may benefit from the advancement of ATR-04 as a potential new treatment option.
• Consumers interested in cosmetic skincare may benefit from the development of ATR-COSF for reducing fine lines and improving elasticity.

Next Steps

• Report initial results from the first-in-human cosmetic study of ATR-COSF by year-end 2026.
• Report topline data from Cohort 1 of the ATR-04 Phase 1/2 trial in Q4 2026.
• Proceed to Cohort 2 of the ATR-04 Phase 1/2 trial.
• Enroll approximately 24 patients in Cohort 2 of the ATR-04 trial for 28 days of once-daily treatment.

Key Dates

Recommendation

The company is making progress on its key development programs with promising early data, and has potential for future capital infusion. However, it continues to operate at a net loss, and the success of its pipeline is contingent on future clinical trial results and regulatory approvals. A 'hold' recommendation reflects the speculative nature of clinical-stage biotechs, balancing potential upside with inherent risks.

Keywords

dermatology, biopharmaceutical, clinical stage, ATR-COSF, ATR-04, cosmetic, rash, R&D